Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Beta Bionics (BBNX) Current Deferred Revenue (2023 - 2025)

Historic Current Deferred Revenue for Beta Bionics (BBNX) over the last 3 years, with Q3 2025 value amounting to $1.3 million.

  • Beta Bionics' Current Deferred Revenue changed N/A to $1.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $1.3 million, marking a year-over-year change of. This contributed to the annual value of $939000.0 for FY2024, which is 97931.03% up from last year.
  • Per Beta Bionics' latest filing, its Current Deferred Revenue stood at $1.3 million for Q3 2025.
  • In the past 5 years, Beta Bionics' Current Deferred Revenue ranged from a high of $1.3 million in Q3 2025 and a low of $87000.0 during Q4 2023
  • Moreover, its 3-year median value for Current Deferred Revenue was $949000.0 (2025), whereas its average is $891600.0.
  • Over the last 5 years, Beta Bionics' Current Deferred Revenue had its largest YoY gain of 97931.03% in 2024, and its largest YoY loss of 97931.03% in 2024.
  • Over the past 3 years, Beta Bionics' Current Deferred Revenue (Quarter) stood at $87000.0 in 2023, then soared by 979.31% to $939000.0 in 2024, then surged by 42.92% to $1.3 million in 2025.
  • Its Current Deferred Revenue was $1.3 million in Q3 2025, compared to $1.1 million in Q2 2025 and $949000.0 in Q1 2025.